CONMED Corp.
https://www.conmed.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CONMED Corp.
Pharma Looks To America First: US FDA Holds Overwhelming Lead Over EMA In Novel Approvals
A Pink Sheet analysis finds US approval preceded European Union clearance for 80% of products approved in both areas, but when EU approval came first, it beat the FDA by a median of 13 months. US-first approvals came close to six months before the EU.
Sandoz Canada Expands Its Portfolio With Generic Vyvanse Launch
Sandoz Canada brings a lisdexamfetamine generic to the market, while its US filing still has tentative approval. Meanwhile, off-patent group CGPA launches a social media campaign to tackle misinformation surrounding generics.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Project Orbis: More Cancer Drugs Available In Scotland Than England
The UK joined Project Orbis in 2021 with the aim of speeding up the regulatory process for promising cancer drugs, but fewer than half of the drugs licensed under this pathway are available on the NHS in England.
Company Information
- Industry
-
Medical Devices
- Monitoring Equipment & Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Biorez, Inc.
- Buffalo Filter
- Concept, Inc.
- In2Bones Global
- SurgiQuest, Inc.
- Viking Systems
- Linvatec Corporation
- Bionx Implants Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice